Releases
KZR
--
0.00%
--
  • All
  • Financials
  • Insiders
More
Webull provides the latest Kezar Life Sciences (KZR) stock and general news. This information may help you make smarter investment decisions.
About KZR
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small molecule therapeutics to treat autoimmune disorders, cancer, and malignant diseases. Its therapies target protein homeostasis. Its lead development program is KZR-616. KZR-616 is a selective small molecule inhibitor of the immunoproteasome. Its second program focuses on small-molecule modulators of the protein secretion pathway. Its protein secretion program is focused on the areas of oncology, inflammation and immune-oncology.
More